| Cefquinome sulphate |
![]() Last updated: 16/09/2025 |
![]() |
(Also known as: cefquinome sulfate) |
|
|
|
Used for the treatment of bacterial infections in animals caused by some gram-positive and gram-negative micro-organisms | |
|---|---|---|
|
Used, generally as the sulphate, for the treatment of mastitis, respiratory disease, septicaemia, digital dermatitis. Also used for respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. | |
|
Cattle; Pigs |
| Approval status |
|
Approved - usually supplied as a prescription only medicine to be authorised by a veterinarian (POM-V) | |
|---|---|---|
|
Approved |
| Chemical structure |
|
Cefquinome sulphate exhibits chirality, due to the presence of two chiral centres in its cephalosporin core. These stereocentres are at the C6 and C7 positions of the beta-lactam ring, which are configured as (6R,7R) in the active pharmaceutical form. In addition, cefquinome contains a (2Z)-methoxyimino group in its acyl side chain, introducing geometric (cis-trans) isomerism. The Z (cis) configuration enhances resistance to beta-lactamase enzymes, making cefquinome more stable and effective against resistant bacteria. Only the (6R,7R)-(2Z) isomer is used in veterinary medicine, as other stereoisomers would have reduced efficacy or altered pharmacokinetics. | |
|---|---|---|
|
C₂₃H₂₆N₆O₉S₃ | |
|
CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCCC5)C(=O)[O-].OS(=O)(=O)O | |
|
CO/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCCC5)C(=O)[O-].OS(=O)(=O)O | |
|
KYOHRXSGUROPGY-OFNLCGNNSA-N | |
|
InChI=1S/C23H24N6O5S2.H2O4S/c1-34-27-16(14-11-36-23(24)25-14)19(30)26-17-20(31)29-18(22(32)33)13(10-35-21(17)29)9-28-8-4-6-12-5-2-3-7-15(12)28;1-5(2,3)4/h4,6,8,11,17,21H,2-3,5,7,9-10H2,1H3,(H3-,24,25,26,30,32,33);(H2,1,2,3,4)/b27-16-;/t17-,21-;/m1./s1 | |
|
Yes |
| General status |
|
Antibacterial, Antibiotic, Medicinal drug | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cephalosporin | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
Synthetic | ||||||||||||||
|
Short lived, broad-spectrum drug that acts by inhibition of the cell wall synthesis | ||||||||||||||
|
[Beta-lactamase, Agonist] | ||||||||||||||
|
118443-89-3 | ||||||||||||||
|
690-053-1 | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
9577261 | ||||||||||||||
|
Antiinfectants for Systemic use: Antibacterials for systemic use; Antibacterials for intramammary use | ||||||||||||||
|
QJ01DE90; QJ51DA92 | ||||||||||||||
|
No | ||||||||||||||
|
Allowed substance (Table 1: Bovine, Porcine, Equidae) | ||||||||||||||
|
626.7 | ||||||||||||||
|
- | ||||||||||||||
|
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;sulfuric acid | ||||||||||||||
|
- | ||||||||||||||
|
|
||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
Pale yellow crystals | ||||||||||||||
|
|||||||||||||||
| Commercial |
|
|
|||
|---|---|---|---|---|
|
Current | |||
|
1990s, developed; 2000s, wide spread vet use | |||
|
|
|||
|
|
|||
|
Available in a variety of formulations including solutions & suspensions for injection and ointments for topical application | |||
|
Cefquinome sulphate is synthesised through a multi-step chemical process starting from 7-aminocephalosporanic acid (7-ACA), the core structure of cephalosporins. In the first step, 7-ACA is reacted with a tetrahydroquinoline derivative under the influence of trimethyliodosilane, forming an intermediate known as 7-ACQ. This intermediate is then oxidised using hydrogen peroxide, introducing the methoxyimino group that enhances beta-lactamase resistance. Next, 7-ACQ undergoes acylation with an AE-active ester, which installs the quaternary ammonium side chain essential for cefquinome’s broad-spectrum activity and membrane penetration. The resulting cefquinome base is then converted into its sulphate salt form to improve water solubility and stability. Final steps include purification, crystallization, and drying. | |||
|
Published GHG data is not available for most pharmaceuticals. However, according to industry, global averages suggest producing 1 kg of a typical active pharmaceutical ingredient can range from 10 to 100 kg CO₂e for small molecule drugs and potentially up to 1000 kg CO₂e for complex biologicals such as vaccines, depending on the drug type, its formulation, complexity of synthesis, solvent recovery, and energy sources used. |
|
|
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
360 | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
- | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
3.24 X 10-02 | Calculated | - | |||||||
|
-1.49 | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
Low | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
| - | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
Environmental exposure is mainly due to livestock excretion | ||||||||||
| Degradation |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- | ||||||||||
| Soil adsorption and mobility |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
| Fate indices |
|
|
|
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - | |||||||||||||||||||||||||||
| Known metabolites |
None
|
|
| Terrestrial ecotoxicology |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
| - | |||||||||||
|
- | - | - | ||||||||
| - | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- |
|
- | - | - | ||||||
|
- | ||||||||||
| Aquatic ecotoxicology |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - | ||||||||
|
|
| General |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
High (class III) | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
Excreted predominately in the faeces, when intermammarily administered substance is excreted in breast milk | A5 A = EU regulatory and evaluation data as published by EC, EFSA (RAR, DAR & Conclusion dossiers), EMA (e.g. EU Annex III PIC DGD) (EU - Pesticides database; EFSA Scientific Publications ) 5 = Verified data used for regulatory purposes |
- | ||||||||
| Health issues |
|
|
||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
No further information available | ||||||||||||||||||||||||||||
| Handling issues |
|
|
|||
|---|---|---|---|---|
|
Will emit toxic gases when heated to decomposition IMDG Trnsport Hazard Class 9 |
|||
|
Health: H315, H319, H335 Environment: H400, H410 |
|||
|
Not listed (Not listed) | |||
|
UN3077 | |||
|
Packaging group III (minor danger) | |||
|
- |
|
|
|
|
||
|---|---|---|---|
|
cefquinome sulphate | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
cefquinoma | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
| Record last updated: | 16/09/2025 |
| Contact: | aeru@herts.ac.uk |
| Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |
© Copyright University of Hertfordshire, 2026. All Rights Reserved
Your use of this website and its various databases is subject to the terms detailed in the University of Hertfordshire’s copyright and IPR statement that can be found at https://www.herts.ac.uk/about-us/legal. In addition, your use of this website and its various databases is subject to the terms of this additional Copyright Statement and the database Conditions of use document. Unless explicitly stated otherwise, the content of this website and databases are owned and controlled by the University of Hertfordshire. Site content, including its selection and arrangement, is owned by the University of Hertfordshire and is protected by copyright and other laws. Except as otherwise expressly permitted under copyright law or within the database Conditions of Use document, the content of this site may not be copied, reproduced, republished, downloaded, posted, broadcast or transmitted in any way without first obtaining the University of Hertfordshire’s written permission. By using our databases the user is deemed to have agreed to comply with all of the terms and conditions as described above and within all relevant documentation.



